Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens

被引:6
|
作者
Kader, Yasser Abdel [1 ]
El-Nahas, Tamer [1 ]
Sakr, Amr [1 ]
机构
[1] Cairo Univ, Dept Clin Oncol, Cairo, Egypt
来源
ONCOTARGETS AND THERAPY | 2013年 / 6卷
关键词
taxane; epirubicin; adjuvant; breast cancer; DOCETAXEL; PACLITAXEL; BENEFIT; TAXANES;
D O I
10.2147/OTT.S48397
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Based on the variable benefit of taxanes in the adjuvant setting of early breast cancer in certain tumor phenotypes, especially in human epidermal growth factor receptor (HER) 2-positive and triple-negative disease, and with the observation of a lesser benefit in luminal A, this research article aimed at exploring the value of docetaxel in patients with an estrogen receptor-positive, HER2-negative disease phenotype, who might not derive the same benefits as those with other phenotypes. Patients and methods: This was a randomized prospective study comparing disease-free survival (DFS) and safety profile of sequential adjuvant three cycles Fluorouracil, Epirubicin, Cyclophosphamide followed by three cycles Docetaxel (FEC-D) versus six cycles classic Fluorouracil, Epirubicin, Cyclophosphamide (FEC)-100 in 60 Egyptian women who presented to Dar Al Fouad Hospital during the period June 2007 to July 2008 with (pT1-2 pN0-3 M0). The primary end point was DFS in a follow-up period of 4 years. The secondary end point was toxicity profile. Results: Four-year DFS rates were comparable in both arms: 73.3% +/- 8.1% in the FEC-D arm versus 76.5% +/- 7.8% in the FEC-100 arm (P = 0.83). N3 and grade III subgroups achieved the worst DFS in both subgroups (P = 0.001 and P = 0.214, respectively). The rate of nausea and vomiting was higher in the FEC-100 arm (P = 0.49), while grade III-IV neutropenia and febrile neutropenia incidence was similar between both arms. Conclusion: Sequential adjuvant chemotherapy with FEC followed by docetaxel achieved comparable DFS results to FEC alone in luminal A phenotype subgroups of breast cancer.
引用
收藏
页码:1073 / 1077
页数:5
相关论文
共 50 条
  • [21] Effect of Chemotherapy for Luminal A Breast Cancer
    Uchida, Naotaka
    Suda, Takako
    Ishiguro, Kiyosuke
    YONAGO ACTA MEDICA, 2013, 56 (02) : 51 - 56
  • [22] Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer
    Irwin, E
    Arnold, A
    Whelan, TJ
    Reyno, LM
    Cranton, P
    PATIENT EDUCATION AND COUNSELING, 1999, 37 (03) : 283 - 291
  • [23] Adjuvant chemotherapy for breast cancer
    Marjorie C. Green
    Gabriel N. Hortobagyi
    Langenbeck's Archives of Surgery, 2002, 387 : 109 - 116
  • [24] Adjuvant chemotherapy of gastric cancer: which regimens?
    De Vita, Ferdinando
    Orditura, M.
    Ciardiello, F.
    Catalano, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 102 - 105
  • [25] Adjuvant chemotherapy in breast cancer
    Bartsch, R.
    Steger, G. G.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2008, 1 (02) : 91 - 98
  • [26] Adjuvant chemotherapy in breast cancer
    Solignac, M
    DIABETES & METABOLISM, 1999, 25 (06)
  • [27] Adjuvant chemotherapy for breast cancer
    Rouesse, J
    MenuBrantome, A
    PRESSE MEDICALE, 1996, 25 (35): : 1731 - 1736
  • [28] Adjuvant chemotherapy for breast cancer
    Green, MC
    Hortobagyi, GN
    LANGENBECKS ARCHIVES OF SURGERY, 2002, 387 (3-4) : 109 - 116
  • [29] Adjuvant chemotherapy in breast cancer
    R. Bartsch
    G. G. Steger
    memo - Magazine of European Medical Oncology, 2008, 1 (2) : 91 - 98
  • [30] Neo-adjuvant Chemotherapy Prescription in Luminal Breast Cancer in the West of Ireland
    McFeetors, Carson
    Bouz, L.
    Davey, C.
    Kerin, E.
    Davey, M.
    McLaughlin, R.
    Sweeney, K.
    Malone, C.
    Barry, M.
    Lowery, A.
    Kerin, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (SUPPL 2) : 57 - 57